Analyst Reco. ResMed, Inc.

Equities

RMD

US7611521078

Advanced Medical Equipment & Technology

Market Closed - Nyse Other stock markets 02:30:02 14/02/2026 am IST			5-day change	1st Jan Change
252.55 ^USD	+2.78%		-7.02%	+4.85%

06/02	Resmed Insider Sold Shares Worth $502,620, According to a Recent SEC Filing	MT
06/02	ResMed Chief Legal Officer Sells 50 Common Shares Of Firm	MT

Analyst Reco.

02/02	Morgans Financial Upgrades ResMed to Buy from Accumulate, Price Target is AU$47.73	MT
02/02	Analyst recommendations: Apple, Autodesk, Best Buy, Caterpillar, PayPal…
30/01	RBC Raises Price Target on ResMed to $314 From $311, Keeps Outperform Rating	MT
30/01	Wolfe Adjusts Price Target on ResMed to $230 From $225, Maintains Underperform Rating	MT
30/01	Wells Fargo Adjusts Price Target on ResMed to $270 From $265, Maintains Equalweight Rating	MT
30/01	KeyBanc Adjusts Price Target on ResMed to $302 From $299, Maintains Overweight Rating	MT
30/01	Stifel Adjusts Price Target on ResMed to $265 From $260, Maintains Hold Rating	MT
30/01	Jefferies Adjusts Price Target on ResMed to $290 From $285, Maintains Hold Rating	MT
30/01	Citigroup Adjusts Price Target on ResMed to $345 From $330, Maintains Buy Rating	MT
30/01	Baird Adjusts Price Target on ResMed to $281 From $275, Maintains Neutral Rating	MT
30/01	Piper Sandler Adjusts Price Target on ResMed to $275 From $270, Maintains Neutral Rating	MT
27/01	Morgan Stanley Adjusts ResMed Price Target to $310 From $305	MT
18/12	Stifel Nicolaus Adjusts ResMed Price Target to $260 From $270, Maintains Hold Rating	MT
17/12	North American Morning Briefing : Stock Futures, Oil Rise After Venezuela Blockade -2-	DJ
16/12	Baird Downgrades ResMed to Neutral From Outperform, Adjusts Price Target to $275 From $300	MT
16/12	Analyst recommendations: Accenture, Albemarle, Eli Lilly, Gitlab, Okta…
31/25/31	Baird Adjusts Price Target on ResMed to $300 From $320	MT
31/25/31	Jefferies & Co Adjusts ResMed Price Target to $285 From $290	MT
31/25/31	Wells Fargo Adjusts ResMed Price Target to $265 From $280	MT
31/25/31	Wolfe Research Adjusts ResMed Price Target to $225 From $215	MT
31/25/31	Morgan Stanley Adjusts ResMed Price Target to $305 From $304	MT
31/25/31	Mizuho Adjusts Price Target on ResMed to $300 From $310	MT
31/25/31	KeyBanc Adjusts Price Target on ResMed to $299 From $298	MT
31/25/31	RBC Lifts Price Target on ResMed to $303 From $300, Keeps Outperform Rating	MT
31/25/31	Morgan Stanley Lifts Price Target on ResMed to $305 From $304, Keeps Overweight Rating	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

ResMed's innovation-driven success and prospects

October 31, 2025 at 02:25 pm IST